Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.20 Consensus Target Price from Analysts

Key Points

• Enliven Therapeutics, Inc. has received an average recommendation of "Buy" from five analysts, with an average twelve-month price target of $41.20.
• Insider trading reports indicate that COO Anish Patel and CEO Samuel Kintz sold shares of the company, leading to minor decreases in their stock holdings.
• The company's shares were trading at $19.22, with a market capitalization of $943.13 million and a significant insider ownership of 25.90%.

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) have been given an average rating of "Buy" by the five ratings firms that are currently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $41.20.

ELVN has been the topic of a number of analyst reports. The Goldman Sachs Group initiated coverage on shares of Enliven Therapeutics in a research note on Monday, June 16th. They set a "buy" rating and a $37.00 price objective on the stock. Robert W. Baird lifted their price target on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, June 16th. HC Wainwright lifted their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. Finally, Jones Trading dropped their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research note on Friday, May 16th.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $20.46, for a total transaction of $66,495.00. Following the sale, the chief financial officer directly owned 23,000 shares in the company, valued at $470,580. This represents a 12.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samuel Kintz sold 12,500 shares of the business's stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $22.52, for a total transaction of $281,500.00. Following the sale, the chief executive officer owned 940,392 shares in the company, valued at $21,177,627.84. This trade represents a 1.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 99,084 shares of company stock valued at $2,046,719 in the last quarter. Corporate insiders own 25.90% of the company's stock.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Polar Capital Holdings Plc boosted its holdings in shares of Enliven Therapeutics by 267.6% in the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after acquiring an additional 1,739,668 shares during the period. Boxer Capital Management LLC acquired a new stake in shares of Enliven Therapeutics during the fourth quarter worth $15,106,000. Candriam S.C.A. purchased a new position in Enliven Therapeutics in the 2nd quarter valued at $8,358,000. Janus Henderson Group PLC grew its position in Enliven Therapeutics by 27.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock valued at $30,001,000 after buying an additional 290,153 shares during the last quarter. Finally, FMR LLC grew its position in Enliven Therapeutics by 3.2% in the 4th quarter. FMR LLC now owns 6,495,871 shares of the company's stock valued at $146,157,000 after buying an additional 199,692 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Price Performance

NASDAQ:ELVN traded down $0.38 during midday trading on Tuesday, hitting $17.52. The company's stock had a trading volume of 298,296 shares, compared to its average volume of 368,666. The firm has a market cap of $859.71 million, a P/E ratio of -9.20 and a beta of 0.93. Enliven Therapeutics has a fifty-two week low of $13.30 and a fifty-two week high of $30.03. The firm's 50 day moving average is $20.85 and its 200-day moving average is $20.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). As a group, analysts forecast that Enliven Therapeutics will post -1.95 EPS for the current year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.